所有图片(1)
别名:
Nizatidine, LY 139037, N′-[2-[[[2-[(Dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N-methyl-2-nitro-1,1-ethenediamine, N-{2-[2-(N,N-Dimethylaminomethyl)-4-thiazolylmethylthio]ethyl}-N′-methyl-2-nitro-1,1-ethenediamine
经验公式（希尔记法）:
C12H21N5O2S2
推荐产品
生化/生理作用
Nizatidine is a potent and selective antagonist of histamine H2 receptors used for treatment of stomach and intestine ulcers. Also, it was recommended as a component of combination therapy for cancer treatment. New data indicate that it can be repurposed to treat subtypes of clear cell renal cell carcinoma (ccRCC) in patients expressing certain isoforms of the pyruvate kinase muscle type. Additionally, nizatidine increases utrophin A levels in in C2C12 myoblasts (relevant to Duchenne muscular dystrophy).
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
T M Lin et al.
The Journal of pharmacology and experimental therapeutics, 239(2), 406-410 (1986-11-01)
Nizatidine (LY139037), a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion. It was 17.8 times as active as cimetidine on histamine (10(-5) M)-induced secretion from the isolated gastric mucosa of the bullfrog. Nizatidine was 8.9 times
Xiangyu Li et al.
Heliyon, 6(2), e03440-e03440 (2020-02-26)
Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of kidney cancer diagnoses and displays high molecular and histologic heterogeneity. Hence, it is necessary to reveal the underlying molecular mechanisms involved in progression of ccRCC to better stratify the patients
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门